Ocular Therapeutix, Inc.
OCULNASDAQHealthcare● Active
$8.16
$-0.09(-1.09%)
Market Cap$1.8B
P/E Ratio—
52W High$16.44
52W Low$6.23
Ocular Therapeutix, Inc. (OCUL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OCUL · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 5, 2026EPS Actual
-$0.41
Est. -$0.32 · -28.1%
Revenue
$0.01B
Est. $0.01B · -15.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 5, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
OCUL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | -$0.40 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 5, 2026 | -$0.32 | -$0.41 | -28.1% | $0.01B | $0.01B | -15.2% |
| ▲ Q1 FY2026 | Feb 5, 2026 | -$0.33 | -$0.29 | +12.1% | $0.01B | $0.02B | -17.9% |
| ▲ Q4 FY2025 | Nov 4, 2025 | -$0.39 | -$0.37 | +5.1% | $0.01B | $0.02B | -9.9% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -$0.35 | -$0.39 | -11.4% | $0.01B | $0.01B | -7.6% |
| ▼ Q2 FY2025 | May 5, 2025 | -$0.29 | -$0.37 | -27.6% | $0.01B | $0.01B | -18.8% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -$0.24 | -$0.29 | -20.8% | $0.02B | $0.02B | -0.2% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.23 | -$0.26 | -13.0% | $0.02B | $0.02B | -8.7% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
-$0.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 5, 2026Miss
EPS Actual
-$0.41
EPS Est.
-$0.32
EPS Surpr.
-28.1%
Revenue
$0.01B
Q1 FY2026
Feb 5, 2026Beat
EPS Actual
-$0.29
EPS Est.
-$0.33
EPS Surpr.
+12.1%
Revenue
$0.01B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
-$0.37
EPS Est.
-$0.39
EPS Surpr.
+5.1%
Revenue
$0.01B
Q3 FY2025
Aug 5, 2025Miss
EPS Actual
-$0.39
EPS Est.
-$0.35
EPS Surpr.
-11.4%
Revenue
$0.01B
Q2 FY2025
May 5, 2025Miss
EPS Actual
-$0.37
EPS Est.
-$0.29
EPS Surpr.
-27.6%
Revenue
$0.01B
Q1 FY2025
Mar 3, 2025Miss
EPS Actual
-$0.29
EPS Est.
-$0.24
EPS Surpr.
-20.8%
Revenue
$0.02B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.26
EPS Est.
-$0.23
EPS Surpr.
-13.0%
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.19 | $-0.17 | $-0.14 | 2 |
| Q3 FY2028 | $-0.18 | $-0.16 | $-0.13 | 2 |
| Q2 FY2028 | $-0.18 | $-0.16 | $-0.13 | 2 |
| Q1 FY2028 | $-0.18 | $-0.16 | $-0.13 | 2 |
| Q4 FY2027 | $-0.36 | $-0.31 | $-0.25 | 1 |
| Q3 FY2027 | $-0.39 | $-0.34 | $-0.28 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.1B | $0.1B | $0.1B | 4 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 4 |
| Q2 FY2028 | $0.1B | $0.1B | $0.1B | 5 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 5, 2026 | -28.1% | $9.77 | $9.71 | -0.61% |
| ▲ Q1 FY2026 | Feb 5, 2026 | +12.1% | $8.55 | $8.91 | +4.21% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +5.1% | $11.41 | $10.90 | -4.47% |
| ▼ Q3 FY2025 | Aug 5, 2025 | -11.4% | $12.35 | $12.00 | -2.83% |
| ▼ Q2 FY2025 | May 5, 2025 | -27.6% | $8.80 | $7.73 | -12.16% |
| ▼ Q1 FY2025 | Mar 3, 2025 | -20.8% | $7.14 | $5.93 | -16.95% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -13.0% | $10.60 | $9.92 | -6.42% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -9.1% | $7.89 | $8.37 | +6.08% |
Q2 FY2026-0.61%
Report Date
May 5, 2026
EPS Beat/Miss
-28.1%
Price Before
$9.77
Price After
$9.71
Q1 FY2026+4.21%
Report Date
Feb 5, 2026
EPS Beat/Miss
+12.1%
Price Before
$8.55
Price After
$8.91
Q4 FY2025-4.47%
Report Date
Nov 4, 2025
EPS Beat/Miss
+5.1%
Price Before
$11.41
Price After
$10.90
Q3 FY2025-2.83%
Report Date
Aug 5, 2025
EPS Beat/Miss
-11.4%
Price Before
$12.35
Price After
$12.00
Q2 FY2025-12.16%
Report Date
May 5, 2025
EPS Beat/Miss
-27.6%
Price Before
$8.80
Price After
$7.73
Q1 FY2025-16.95%
Report Date
Mar 3, 2025
EPS Beat/Miss
-20.8%
Price Before
$7.14
Price After
$5.93
Q4 FY2024-6.42%
Report Date
Nov 14, 2024
EPS Beat/Miss
-13.0%
Price Before
$10.60
Price After
$9.92
Q3 FY2024+6.08%
Report Date
Aug 7, 2024
EPS Beat/Miss
-9.1%
Price Before
$7.89
Price After
$8.37
Avg Beat Reaction-0.13%
Avg Miss Reaction-5.48%
Beat Rate2 / 8 quarters
Largest Move-16.95% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OCUL ends December
Ocular Therapeutix, Inc. (OCUL) most recently reported earnings on May 5, 2026 for Q2 FY2026, posting EPS of $-0.41 — missing the analyst consensus of $-0.32 by -28.1%. The next OCUL earnings date is expected around September 1, 2026.
Each quarter, investors track OCUL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OCUL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OCUL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OCUL earnings · 5 questionsOcular Therapeutix, Inc.'s next earnings report is expected around September 1, 2026. OCUL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OCUL historically reports after market close (AMC).
OCUL earnings datewhen is OCUL earningsOCUL next earnings datewhen does OCUL report earningsOCUL earnings calendar
▸ Source: FMP · Ocular Therapeutix, Inc. SEC filings · US GAAP · Ocular Therapeutix, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026